Suppr超能文献

立体定向放射治疗后复发性特发性三叉神经痛的长期疼痛结局:首次微血管减压术与重复立体定向放射治疗的前瞻性比较

Long-term pain outcomes for recurrent idiopathic trigeminal neuralgia after stereotactic radiosurgery: a prospective comparison of first-time microvascular decompression and repeat stereotactic radiosurgery.

作者信息

Raygor Kunal P, Wang Doris D, Ward Mariann M, Barbaro Nicholas M, Chang Edward F

机构信息

1Department of Neurological Surgery, University of California, San Francisco, California; and.

2Department of Neurological Surgery, Indiana University, Indianapolis, Indiana.

出版信息

J Neurosurg. 2018 Oct 26;131(4):1207-1215. doi: 10.3171/2018.5.JNS172243. Print 2019 Oct 1.

Abstract

OBJECTIVE

Microvascular decompression (MVD) and stereotactic radiosurgery (SRS) are common surgical treatments for trigeminal neuralgia (TN). Many patients who receive SRS have pain recurrence; the ideal second intervention is unknown. The authors directly compared pain outcomes after MVD and repeat SRS in a population of patients in whom SRS failed as their first-line procedure for TN, and they identified predictors of pain control.

METHODS

The authors reviewed a prospectively collected database of patients undergoing surgery for TN between 1997 and 2014 at the University of California, San Francisco (UCSF). Standardized data collection focused on preoperative clinical characteristics, surgical characteristics, and postoperative outcomes. Patients with typical type 1, idiopathic TN with ≥ 1 year of follow-up were included.

RESULTS

In total, 168 patients underwent SRS as their first procedure. Of these patients, 90 had residual or recurrent pain. Thirty of these patients underwent a second procedure at UCSF and had ≥ 1 year of follow-up; 15 underwent first-time MVD and 15 underwent repeat SRS. Patients undergoing MVD were younger than those receiving repeat SRS and were more likely to receive ≥ 80 Gy during the initial SRS. The average follow-up was 44.9 ± 33.6 months for MVD and 48.3 ± 45.3 months for SRS. All patients achieved complete pain freedom without medication at some point during their follow-up. At last follow-up, 80% of MVD-treated patients and 33.3% of SRS-treated patients had a favorable outcome, defined as Barrow Neurological Institute Pain Intensity scores of I-IIIa (p < 0.05). Percentages of patients with favorable outcome at 1 and 5 years were 86% and 75% for the MVD cohort and 73% and 27% for the SRS cohort, respectively (p < 0.05). Multivariate Cox proportional hazards analysis demonstrated that performing MVD was statistically significantly associated with favorable outcome (HR 0.12, 95% CI 0.02-0.60, p < 0.01). There were no statistically significant predictors of favorable outcome in the MVD cohort; however, the presence of sensory changes after repeat SRS was associated with pain relief (p < 0.01).

CONCLUSIONS

Patients who received MVD after failed SRS had a longer duration of favorable outcome compared to those who received repeat SRS; however, both modalities are safe and effective. The presence of post-SRS sensory changes was predictive of a favorable pain outcome in the SRS cohort.

摘要

目的

微血管减压术(MVD)和立体定向放射外科治疗(SRS)是三叉神经痛(TN)常见的外科治疗方法。许多接受SRS治疗的患者会出现疼痛复发;理想的二次干预方法尚不清楚。作者直接比较了SRS作为TN一线治疗失败的患者群体中MVD和重复SRS后的疼痛结局,并确定了疼痛控制的预测因素。

方法

作者回顾了1997年至2014年在加利福尼亚大学旧金山分校(UCSF)进行TN手术的患者的前瞻性收集数据库。标准化的数据收集集中在术前临床特征、手术特征和术后结局。纳入典型1型特发性TN且随访≥1年的患者。

结果

共有168例患者首次接受SRS治疗。其中,90例有残留或复发性疼痛。这些患者中有30例在UCSF接受了二次手术且随访≥1年;15例行初次MVD,15例行重复SRS。接受MVD的患者比接受重复SRS的患者年轻,且在初次SRS期间更有可能接受≥80 Gy的剂量。MVD组的平均随访时间为44.9±33.6个月,SRS组为48.3±45.3个月。所有患者在随访期间的某个时间点均实现了无需药物的完全疼痛缓解。在最后一次随访时,80%接受MVD治疗的患者和33.3%接受SRS治疗的患者获得了良好结局,定义为巴罗神经学研究所疼痛强度评分为I-IIIa级(p<0.05)。MVD队列在1年和5年时良好结局患者的百分比分别为86%和75%,SRS队列分别为73%和27%(p<0.05)。多因素Cox比例风险分析表明,进行MVD与良好结局在统计学上显著相关(风险比0.12,95%置信区间0.02-0.60,p<0.01)。MVD队列中没有统计学上显著的良好结局预测因素;然而,重复SRS后出现感觉改变与疼痛缓解相关(p<0.01)。

结论

SRS失败后接受MVD治疗的患者比接受重复SRS治疗的患者有更长时间的良好结局;然而,两种治疗方式都是安全有效的。SRS后感觉改变的出现可预测SRS队列中良好的疼痛结局。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验